Can statin therapy reduce the risk of breast cancer?

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8553-8555

  Vogel, Victor G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; PROTEIN P21; PROTEIN P27; SIMVASTATIN;

BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HUMAN; META ANALYSIS; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; BREAST TUMOR; FEMALE; NOTE; RISK FACTOR; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33644838159     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6202     Document Type: Editorial

References (21)

1. Coogan PF, Rosenberg L, Palmer JR, et al: Statin use and risk of breast and prostate cancer. Epidemiology 13:262-267, 2002
2. 1 to multiple cell cycles by lovastatin. Cancer Res 51:3602-3609, 1991
3. Addeo R, Altucci L, Battista T, et al: Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 220:864-870, 1996
4. Inano H, Suzuki K, Onoda M, et al: Anti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. Carcinogenesis 18:1723-1727, 1997
5. 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 96:7797-7802, 1999
6. Muck AO, Seeger H, Wallwiener D: Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 42:695-700, 2004
7. Kochhar R, Khurana V, Bejjanki H, et al: Statins reduce breast cancer risk: A case control study in US female veterans. J Clin Oncol 23:7S, 2005 (suppl, abstr 514)
8. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60, 1996
9. Sacks FM, Pfeffer JA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
10. Jacobs D, Blackburn H, Higgins M, et al: Report of the Conference on Low Blood Cholesterol: Mortality associations. Circulation 86:1046-1060, 1992
11. Kritchevsky SB: Dietary lipids and the low blood cholesterol-cancer association. Am J Epidemiol 135:509-520, 1992
12. Blais L, Desgagne A, Lelorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. Arch Intern Med 160:2363-2368, 2000
13. Law MR, Thompson SG, Wald NJ: Assessing possible hazards of reducing serum cholesterol. BMJ 308:373-379, 1994
14. Law MR, Thompson SG: Low serum cholesterol and the risk of cancer: An analysis of the published prospective studies. Cancer Causes Control 2:253-261, 1991
15. Hebert PR, Gaziano JM, Chan KS, et al: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials. JAMA 278:313-321, 1997
16. Bonovas S, Filioussi K, Tsavaris N, et al: Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606-8612, 2005
17. Gordis L: Epidemiology (ed 2). Philadelphia, PA, W.B. Saunders Co., 2000, pp 193-195
18. Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: A proposal for reporting-Meta-Analysis of Observational Studies in Epidemiology (MOOSE) Group. JAMA 283:2008-2012, 2000
19. Sackett DL, Haynes RB, Guyatt GH, et al: Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston, MA, Little, Brown, 1991
20. Etminan M, Coogan PF, Rosenberg L: Statins and cancer: Will we ever know the answer? Epidemiology 13:607, 2002
21. Corsini A, Jacobson TA, Ballantyne CM: Fluvastatin: Clinical and safety profile. Drugs 64:1305-1323, 2004